Cybin Announces Final Approval for Listing on NYSE American

Early Investor Opportunity!

Revealed: Major US Funds Piling Into “Tiny” Biotech Stock…

  • Groundbreaking research team filing key patents in “unorthodox” mental health treatment, 4 promising drugs already in development pipeline…
  • Over US$70M in operational funding already raised by leadership and visionary co-founders…
  • Wall Street funds battling for top shareholder positioning…
  • Recently received Phase II clinical trial approval…

If you’re looking for early investment opportunities in the promising medical psychedelic research space, and you want to position your portfolio before the wall of “dumb money” floods in…keep your eye on Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF). Interest in Cybin, a small psychedelic medical research and development outfit, is surging as global demand for alternative mental health solutions skyrockets. Over the last few months Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF), while researching alternative treatments for mental health issues like depression, PTSD, and addiction, revealed that they’ve now filed 13 key patents for new psychedelic compounds and delivery platforms.

And the profit potential could be massive for early investors… The company that holds the patent rights to the medical solution for debilitating mental health issues could capitalize on this underserved market over the next few years. Pharmaceutical companies and teams of scientists around the world are now racing to develop and control these new life saving psychedelic treatments, patents, and intellectual property. Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) looks to be the winner of the race with patents filed and four promising drugs well into the development pipeline.


A $16 Trillion Dollar Opportunity…According to the World Health Organization, Over 700 Million people worldwide are affected with some sort of mental illness, addiction or eating disorder1. Worldwide, 1 in 4 people will suffer from mental or neurological disorders at some point in their lives2. The National Center for Biotechnology Information (NCBI) estimates3 that worldwide economic output loss from mental health issues like depression and alcohol addiction will cause $16.3 TRILLION in worldwide economic output loss between 2011 and 2030. A global economic output loss higher than cancer or diabetes.


Current treatment solutions, using expensive therapy and lengthy treatment timelines, can’t keep up with demand and or do not effectively work to treat the underlying problem.Until now…
Recent research has revealed treatments such as psilocybin-assisted therapy and other psychedelic options are effective in treating issues such as addiction, post-traumatic stress disorder (PTSD), depression, and numerous other conditions4.

Even better, according to the published research findings, these new psychedelic solutions are producing “large, rapid, and sustained antidepressant effects in patients with major depressive disorder.”


“…on a mission to revolutionize mental healthcare.”

Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF), is on the cutting edge of this new era of mental health treatment. With a visionary leadership consisting of industry veterans and a strong research team of innovative scientists, Cybin – a “tiny” biotech company – has massive levels of output…


  • 13 psychedelic related patents filed…
  • 50 different proprietary psychedelic molecules developed based upon DMT, MDMA, Psilocybin, and other psychedelics…
  • 4 promising active drug programs in the pipeline, with one entering “Phase II” of the development conduit…
  • Leveraging tech and strategic partnerships for advancing new frontiers for treating neurological disorders…
  • Aggressive M&A strategy to access broader markets and investor audiences…
  • Experienced scientific team that has previously brought over 5 drugs to market, overseen 60+ IND programs with the FDA and has collectively been involved in 37 exits across the biotech sector and various other verticals…

Before listing on Canada’s NEO exchange in November 2020, top US funds like RA Capital, Janus Henderson, LifeSci Ventures and others are now major shareholders of company stock. Aiming to reach a wider investment audience, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) has become eligible on the Multijurisdictional Disclosure System (MJDS) for listing on a US Tier 1 exchange.Under the leadership of CEO Doug Drysdale, Cybin is positioning itself to tackle the significant work that remains for creating FDA approved psychedelic drugs that control delivery and deliver quicker results with shorter duration times.With a 30 year veteran in the healthcare sector, Drysdale has built and turned-around 4 pharmaceutical companies, completed 15 corporate acquisitions, and has raised $4 billion of both public and private capital. And according to Drysdale, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) disrupting one of the largest fields in modern medicine is a key component of their growth strategy…


“We are focused on addressing the mental health crisis and transforming the treatment landscape.”– Doug Drysdale, Cybin CEO

To accelerate the growth of the company, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) is deploying a “three pillar” strategy…

  • Pillar #1: New Drug Discovery Platform, includes applying well-known scaffolds including Psilocybin, DMT, and MDMA…
  • Pillar #2: Proprietary Drug Delivery And Formulation using inhalation, sublingual & ODT, and extended-release formulation delivery systems that have the potential to reduce side effects and to control exposure…
  • Pillar #3: Leveraging Tech While Providing New Treatment Regimens For Clinicians, deploying software-based platforms, novel neuroimaging technology, and machine learning based data analytics…


Don’t expect Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) to remain “tiny” once the news about their revolutionary medical breakthroughs goes mainstream.Investors looking for early opportunities in psychedelic medicine should move quickly on Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) and establish a position before the wall or retail and institutional money starts moving in on the opportunity.
CLICK HERE NOW for in-depth investor information on Cybin and the opportunities in the growing psychedelic medicine space.References

1 ( n/) & ( htm) & ( researchers-release-first-report-worldwide-addictionstatistics/)
3 (1)
4 Kyzar, E. J.; Nichols, C. D.; Gainetdinov, R. R.; Nichols, D. E.; Kalueff, A. V., Psychedelic Drugs in Biomedicine. Trends Pharmacol Sci 2017, 38 (11), 992-1005.

Be part of the FutureEnter your email below to get your free early investor report on Cybin, Inc.



This communication is a advertisement. Tips4Traders is a brand name of IRPub LLC and MediaPub Holdings, its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cybin Corp. (OTC: CLXPF | NEO:CYBN) to conduct public investor awareness, distribution and investor education marketing for a period of 45-60 days. Cybin Corp. has paid the Publisher the equivalent of One-Hundred Thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here  and acknowledge that you have reviewed the Disclaimer found here: If you do not agree to the Terms of Use, please contact to discontinue receiving email communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than


All of the content found on this page was authored by our 3rd party affiliate partner. TipsforTraders, IRPub LLC, and our affiliates are not responsible for the content or accuracy of this article.

TipsForTraders, IRPub LLC, DO NOT hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. We have been paid to produce this piece by the Company or companies mentioned above.